CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET

Company Participants

Paul Quinlan - General Counsel

Sujal Shah - President and Chief Executive Officer

Harish Shantharam - Chief Financial Officer

Charles McWherter - Chief Scientific Officer and President of Research and Development

Lewis Stuart - Chief Commercial Officer

Conference Call Participants

Yasmeen Rahimi - Piper Sandler

Steve Seedhouse - Raymond James

Kristen Kluska - Cantor Fitzgerald

Patrick Dolezal - LifeSci Capital

Julian Harrison - BTIG

Jay Olson - Oppenheimer

Ed Arce - H.C. Wainwright

Thomas Smith - Leerink Partners

Mayank Mamtani - B. Riley

Operator

Good day, ladies and gentlemen, and welcome to CymaBay’s Second Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded at the company’s request. It is also being webcast live on the Investors section at the CymaBay website at www.cymabay.com.

Now, I would like to turn the call over to Mr. Paul Quinlan, General Counsel at CymaBay. Mr. Quinlan, please proceed.

Paul Quinlan

Thank you operator and good afternoon everyone. I hope that you have had a chance to review the press release we issued announcing our second quarter 2023 financial results and business updates. You can access that release on our website under the Investors tab.

Joining me on the call today are Sujal Shah, Chief Executive Officer; Chuck McWherter, Chief Scientific Officer and President of R&D; Lewis Stuart, Chief Commercial Officer; and Harish Shantharam, Chief Financial Officer. Following our prepared remarks, we will open the call for Q&A.

Before we begin, I’d like to remind everyone that statements made during this conference call, including the Q&A session relating to CymaBay’s expected future performance, business prospects, events or plans, including clinical plans, regulatory approvals, funding and repayment schedules, anticipated timelines and data release dates, cash runway and planning for commercialization are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995.

Although, the company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, actual outcomes, and results are subject to risks and uncertainties and could differ materially from those forecast due to the impact of many factors. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.